Navigation Links
Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
Date:8/9/2013

DUBLIN, August 9, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/ppq2qd/global_lung) has announced the addition of the "Global Lung Cancer Therapeutics Market 2012-2016" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Global Lung Cancer Therapeutics Market To Grow At A CAGR Of 13.26 Percent Over The Period 2012-2016

The Global Lung Cancer Therapeutics Market 2012-2016 report has been prepared based on an in-depth analysis of the market with inputs from industry experts.

Commenting on the report, an analyst from the healthcare team said: "There has been an increase in medical tourism in the APAC region. Patients from all around world are visiting countries such as China and India for treatments. The healthcare facilities in the APAC region are improving, with excellent healthcare providers providing better treatment for diseases such as cancer or any other treatment at a low cost. Thus, the increase in the number of patients coming to China and India for cancer treatment is a growing trend, which is encouraging the healthcare organizations to opt for more lung cancer therapeutic drugs."

According to the report, one of the major growth factors driving the Global Lung Cancer Therapeutics market is the increase in the prevalence of cancer patients worldwide. Therapeutic drugs are among the remedies for cancer, and hence healthcare organizations are opting for lung cancer therapeutic drugs for treatments. Moreover, most of the vendors are focusing significantly on the US market, which is expected to witness a faster growth rate than the global CAGR during the period 2012-2016.


Key Topics Covered

1. Executive Summary
2. Introduction
3. Market Coverage
4. Market Landscape
5. Geographical Segmentation
6. Key Leading Countries
7. Rate of Incidence and Prevalence
8. Vendor Landscape
9. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
16. Other Reports in this Series 

Companies Mentioned

- ARIAD Pharmaceuticals
- Ambit Biosciences
- AstraZeneca
- Biogen Idec
- Bristol-Myers Squibb
- Cephalon
- Clavis Pharma
- ERYtech Pharma
- Eisai
- Eli Lilly
- Genmab
- Genzyme
- GlaxoSmithKline
- Hoffmann-La Roche
- Novartis
- Pfizer
- Sunesis Pharmaceuticals
- Talon Therapeutics
- Teva Pharmaceutical Industries

For more information visit http://www.researchandmarkets.com/research/ppq2qd/global_lung

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Lung Cancer



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 ... better understand Enzo Biochem and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017  The National ... has joined the health policy research organization as its ... Medical and Regulatory Affairs ( North America ... Board of Directors. "We,re pleased to have ... NPC President Dan Leonard . "We welcome their ...
(Date:3/28/2017)... March 28, 2017 Biostage, Inc. ... developing bioengineered organ implants to treat cancers and other ... announced that Jim McGorry, CEO of Biostage, ... panel at the MassBio 2017 Annual Meeting ... ET in Cambrige, Massachussetts. The 3D Printing and ...
(Date:3/28/2017)... March 28, 2017 Focus ... unpredictable sector due to the scientifically intensive operations ... medical, agricultural, environmental, and industrial. In today,s pre-market research, ... Pharmaceuticals Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: OVAS), ... Inc. (NASDAQ: OCUL ). Learn more ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
Breaking Biology News(10 mins):